Illumina illegally monopolised DNA sequencing market, rival says

Ben Remaly

12 January 2021

Shutterstock/Sundry Photography

Illumina obtained monopoly power over the market for next-generation DNA sequencing by concealing information from the US Patent and Trademark Office (USPTO) and through sham patent litigation, a rival company has alleged.

Subscribe to Global Competition Review

Subscribe and start reading now

Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.

Subscribe now

Already have access? Login below

Ben Remaly

View full biography

Author | Senior news reporter, Global Competition Review

[email protected]

Tipline

Born to run: The Tipline for 28 January 2021
Antitrust litigation is often more like a marathon than a sprint – unless you’re in charge of the Federal Trade Commission’s bureau of competition. The outgoing director last year sacrificed a six-year streak of striding 26.2 miles in one go as his agency brought more than 30 enforcement actions in merger cases alone. In today’s Tipline, Ian Conner discusses his tenure at the FTC, Facebook says it faces an “uphill battle” against Apple’s “dominant …
Chief antitruster: The Tipline for 27 January 2021
Pay-for-delay-ception: The Tipline for 26 January 2021

Illumina illegally monopolised DNA sequencing market, rival says

Subscribe to Global Competition Review

Subscribe and start reading now

Already have access? Login below

Related Topics

Ben Remaly